SCHEMBL7225974

SCHEMBL7225974

COc1ccc2c(c1)nc([S+]([O-])Cc1ncc(C)c(OC)c1C)n2S(=O)(=O)c1ccc(OCCN(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.40
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
HTR6 P50406 10/20 0.38
ALDH1A1 P00352 3/20 0.37
HTT P42858 3/20 0.37
WDR5 P61964 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
BRS3 P32247 2/20 0.37
DRD3 P35462 2/20 0.37
KDM4E B2RXH2 1/20 0.37
DDAH1 O94760 1/20 0.37
ABCB11 O95342 1/20 0.37
ATP1A1 P05023 1/20 0.37
ATP1B1 P05026 1/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37
ABCB1 P08183 1/20 0.37
CYP3A4 P08684 1/20 0.37
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7225983 0.94 CYP2C9 (0.42) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7009476 0.91 CYP2C9 (0.45) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7008144 0.90 CYP2C9 (0.41) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7225976 0.90 CYP2C9 (0.37) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7008048 0.90 CYP2C9 (0.42) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7009636 0.89 CYP2C9 (0.44) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7013702 0.89 CYP2C9 (0.43) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL5339696 0.89 CYP2C9 (0.43) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7013356 0.88 CYP2C9 (0.43) CYP2C9KMT2AMEN1HTR6ALDH1A1
SCHEMBL7008197 0.88 CYP2C9 (0.43) CYP2C9KMT2AMEN1HTR6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US claimed
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed